ClinicalTrials.Veeva

Menu
New Mexico Clinical Research and Osteoporosis Center | Albuquerque, NM logo

New Mexico Clinical Research and Osteoporosis Center | Albuquerque, NM

Research site

Site insights

Top conditions

Top treatments

Zoledronic Acid
MK-0616
RN316
BI 690517
ALX1-11
CC-93538
Tanezumab
PF-04950615
Empagliflozin
Teriparatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Mary Niles

Verified by this site

Active trials

7 of 55 total trials

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Enlicitide Decanoate
Drug: Placebo

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling
Hypertension
Cardiovascular Diseases
Drug: Placebo matching Vicadrostat
Drug: Vicadrostat

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Active, not recruiting
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs...

Active, not recruiting
Osteogenesis Imperfecta
Other: Placebo
Biological: Setrusumab

Trial sponsors

Pfizer logo
MannKind logo
Boehringer Ingelheim logo
Celgene logo
Merck Sharp & Dohme (MSD) logo
Shire logo
Bristol-Myers Squibb (BMS) logo
Ironwood Pharmaceuticals logo
Lilly logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems